Folgen
-
Join in, to hear Dr Jesse Boehm discuss the convergence of advancements that are making precision medicine more effective for a larger percentage of patients. He touches on how access to molecular profiling has become more widespread and affordable, allowing more patients to get detailed molecular information about their tumors. Dr. Boehm then mentions how new types of chemistry and drug development are making it possible to target a wider range of cancer proteins. He goes on to describe how innovations in biopsies enable real-time monitoring of tumors, providing a comprehensive molecular portrait of the tumorâs evolution. Overall, Dr. Boehm is optimistic that these and the other advancements that he discusses will significantly improve the outcome for most cancer patients within the next few decades.
-
In this episode, Dr Jesse Boehm relates his inspiring journey into the world of translational research. Dr Boehm focuses on how his laboratory engineered solutions to complex biological problems, particularly cancer. He stresses the importance of working alongside cancer patients, sharing a very personal story and the impact it had on his perspective. Thanks to this perspective, Dr. Boehm encourages cancer scientists to consider urgency and patient impact of their research.
-
Fehlende Folgen?
-
In this episode, Dr. Jesse Boehm discusses the importance of collaboration in cancer research. Dr. Boehm touches on some of the partnerships that he has been involved in, such as the large collections of organoids and cell models in the Human Cancer Models Initiative. Although logistical and bureaucratic can challenge these cross-institutional partnerships, Dr. Boehm shares the key ingredients that make collaboration more feasible. Dr Boehm also notes that the urgency seen during the recent pandemic should be applied to cancer research to drive significant progress.
-
In this episode, David Yarmosh and Tasha Santiago-Rodriguez delve into their unexpected journeys into bioinformatics and data science. Tasha shares her transition from wet lab work to data science, emphasizing the importance of reproducibility and proper experimental controls in microbiome research. Finally, Tasha reflects on her work with ancient DNA and microbiomes, viewing it as a way of revealing history and making history by uncovering details about ancient cultures.
-
Here, Nick Greenfield discusses the evolution of One Codex from a microbiome analysis company to an integrated end-to-end provider. Greenfield brings up a few ideas that he has been incubating, particularly around large language models and data visualization. In a discussion about the future of One Codex, Greenfield shares upcoming changes to his organizationâs business model. He also remarks on the challenges of maintaining and updating their database due to the constant changes in taxonomy.
-
In this episode Nick Greenfield, the founder of One Codex, discusses his transition from a background in environmental studies and international relations to establishing a microbiome company. He touches on his experience entering a contest by the Defense Threat Reduction Agency in 2013, aimed at developing better metagenomics algorithms. Despite not winning, the positive feedback on their prototypeâs ease of use revealed a market gap. This led to the creation of One Codex. Greenfield further expostulates on the challenges and lessons learned during the construction of the first metagenomic database for One Codex.
-
In this episode Nick Greenfield, the founder of One Codex, describes his organizationâs evolution from a microbiome analysis company in 2014 to a full-service microbial company. Mr. Greenfield shares his transition from CEO to board chair, reflecting on the early days of One Codex when there was no market. He also emphasizes the companyâs focus on reducing complexity for the user, providing a high-quality result, and making new types of data more accessible for a large audience. Mr. Greenfield then shares some of One Codexâ positive contributions to the biological community and the general market.
-
In this episode, James Crill delves into the future of microbial forensics, emphasizing the importance of fully vetted databases for microbial forensics and the impact of rapid technological advancements. Mr. Crill discusses the evolution of sequencing technologies, from large laboratory equipment to more mobile and efficient technologies. He underscores the urgency for data validation and authentication due to the influx of diverse data and the ongoing changes in sequencing technologies. Crill closes by discussing the importance of studying microbial forensics and microbial communities, emphasizing the need for continued research and development of new techniques in this field.
-
In this episode, James Crill discusses his unconventional career path, highlighting his transition from healthcare to academia and research. He underscores the importance of adaptability, hard work, and openness to new opportunities in shaping oneâs career. Mr. Crillâs experiences in various roles, from industry to academia, and the challenges faced during these transitions are discussed. He then focuses on the influence of his previous roles in government and industry on his current work and the unique challenges presented by mobile lab deployment.
-
In this episode, Jamie Crill discusses his research focus of microbial forensics, particularly the origins of bacteria and yeast. Join us as we engage discussion about how to use microorganisms to determine if a crime was a biological one, or if these microbes can clarify when and where a person has been recently. Additionally, Dr. Crill will discuss what the current methods are for determination, and what it's like to teach these skills to graduate students.
-
In the third episode in this series, Dr. Birgitt Schuele shares her insights on the current state and future directions of this field, from diagnosis and care to mechanisms and treatments. She also tells us about her own work on using machine learning to study mouse behavior in the dark, and creating 3D organ models from stem cells to simulate drug responses. She explains how these technologies can help us understand our own biology better, and reduce the need for animal models and human trials. She also discusses the challenges and limitations of creating a simulated human that can capture the complexity and diversity of individual biology.
-
In this second episode of the series, Dr. Birgitt Schuele discusses how the study of Parkinsonâs disease has transformed over the years, from gel bands done by hand to modern sequencing technologies. Dr. Schuele then detours to how we as scientists recognize research in todayâs big data biology. We also find an answer to the question âwhat does a researcher gain through personal interactions with their patients?â Join us in our conversation to hear Birgittâs take on these topics and more!
-
We kick off this season of ATCCâs podcast with insights from Dr. Birgitt Schuele on Parkinsonâs disease. In this episode, she discusses the physical and cognitive changes brought on by the disease, and zeros in on some of the genetic components. Dr. Schuele then talks about her current focus of research, the role of alpha synuclein in the onset and progression of Parkinsonâs. She touches on some of the daunting challenges that researchers face when looking for biomarkers and druggable targets to treat the disease. Finally, Dr. Schuele goes back to her roots to share with us how she ended up studying this devastating neurodegenerative disease.
-
In the final episode of season one of ATCCâs podcast, John Bagnoli peers into the future of bioinformatics and describes the challenges that are likely to appear along the way. Heâll explore important questions such as: Will bench scientists become the bioinformaticians as the bioinformaticians transition into software development? Will machine learning and robotics replace humans in the laboratory all together? Listen in, to hear Johnâs surprising answers.
-
In this episode ATCCâs John Bagnoli reminisces about his role in the response to the 2014 Ebola virus epidemic in western Africa. Mr. Bagnoli does a deep dive into the challenges that he faced while running a biosafety level 4 laboratory in a shipping container. He then pivots to discussing how these experiences have informed his management style, giving Bagnoli a new appreciation for logistics, communication, teamwork, and patience.
- Mehr anzeigen
